No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case–control study and meta-analysis

Yui, Naoe; Shinkai, Takahiro; Hori, Hiroko; Fukunaka, Yuko; Utsunomiya, Kensuke; Sakata, Sei-ichiro; Matsumoto, Chima; Shimizu, Kazuko; Hwang, Rudi; Ohmori, Osamu; Nakamura, Jun

doi:10.1016/j.neulet.2007.01.006

Cited by 67 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study performed in a Japanese cohort, the BDNF Val66Met variant was significantly associated with age of onset in patients with schizophrenia [Numata et al, [2006]]. However, this finding was not confirmed by an independent study [Naoe et al, [2007]], and was not observed in a Caucasian cohort [Gourion et al, [2005]]. The association between the BDNF Val66Met genotype and age of onset of schizophrenia may be ethnic group specific, but needs to be validated by further investigation in larger study populations.…”

mentioning

confidence: 88%

BDNF Val66Met variant and age of onset in schizophrenia

Chao

Kao

Porton

2008

American J of Med Genetics Pt B

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) has been advanced as a candidate gene for schizophrenia by virtue of its effects on neurotransmitter systems that are dysregulated in psychiatric disorder and its involvement in the response to antipsychotic drugs. The extensively examined BDNF gene Val66Met (or rs6265) variant has been associated with schizophrenia, and studies have linked this polymorphism to brain morphology, cognitive function, and psychiatric symptoms in schizophrenia. Moreover the BDNF Val66Met variant has been reported to be associated with age of onset in schizophrenia. Genotyping of African-American subjects with schizophrenia for five BDNF coding region single nucleotide polymorphisms revealed variance only at the Val66Met allele. The results of statistical analyses indicate a relationship between the BDNF Val66Met genotype and the ages of first psychiatric hospitalization and first schizophrenia symptoms.

show abstract

mentioning

confidence: 88%

BDNF Val66Met variant and age of onset in schizophrenia

Chao

Kao

Porton

2008

American J of Med Genetics Pt B

View full text Add to dashboard Cite

show abstract

“…Because impaired learning and memory are core symptoms of SZ, BDNF may be involved in this pathological condition. In addition, the V66M allele in some instances has been linked to development of SZ (Numata et al, 2006); although there is conflicting evidence (Naoe et al, 2007;Pillai, 2008). It will be necessary to determine whether these opposite outcomes are due to varying endophenotypes of the heterogeneous disease, patient population background, or affective symptoms versus developmental/neurochemical phenotypes of SZ.…”

Section: E Brain-derived Neurotrophic Factor Polymorphisms and Schizmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders

Autry

Monteggia²

2012

Pharmacol Rev

1,190

764

View full text Add to dashboard Cite

“…A variant in the gene encoding brain-derived neurotrophic factor (BDNF) has been studied extensively for association with schizophrenia. Although findings from several meta-analyses have been equivocal Gratacos et al, 2007;Kanazawa et al, 2007;Naoe et al, 2007;Qian et al, 2007;Xu et al, 2007), some favor the existence of an association, albeit of low increased risk and likely including multiple causal variants.…”

Section: Introductionmentioning

confidence: 99%

Effects of brain‐derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia

et al. 2010

View full text Add to dashboard Cite

A functional polymorphism of the brain-derived neurotrophic factor (BDNF) gene (Val66Met) has been associated with the risk for schizophrenia and volume differences in the hippocampus. However, little is known about the association between progressive brain volume change in schizophrenia and BDNF genotype. The aim of this study was to investigate the relationship between hippocampal volume change in patients with schizophrenia and healthy control subjects and BDNF genotype. Two structural magnetic resonance imaging brain scans were acquired of 68 patients with schizophrenia and 83 healthy subjects with an interval of approximately 5 yrs. Hippocampal volume change was measured and related to BDNF genotype in patients and healthy controls. BDNF genotype was not associated with hippocampal volume change over time in patients or healthy controls, nor could we replicate earlier findings on smaller hippocampal volume in Met-carriers. However, we did find a genotype-by-diagnosis interaction at baseline demonstrating smaller hippocampal volumes in patients homozygous for the Val-allele relative to healthy Val-homozygotes. In addition, irrespective of genotype, patients showed smaller hippocampal volumes compared with healthy controls at baseline. In summary, our results suggest that the BDNF Val66Met polymorphism is not associated with hippocampal volume change over time. Nevertheless, our findings may support the possibility that BDNF affects brain morphology differently in schizophrenia patients and healthy subjects.

show abstract

No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case–control study and meta-analysis

Cited by 67 publications

References 26 publications

BDNF Val66Met variant and age of onset in schizophrenia

BDNF Val66Met variant and age of onset in schizophrenia

Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders

Effects of brain‐derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia

Contact Info

Product

Resources

About